Tema Oncology ETF
CANCDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 11, 2025 | $0.02 | 2025-12-10 | 2025-12-10 |
| December 12, 2024 | $0.73 | 2024-12-11 | 2024-12-11 |
| December 15, 2023 | $0.15 | 2023-12-13 | 2023-12-14 |
Dividends Summary
- Consistent Payer: Tema Oncology ETF has rewarded shareholders with 3 dividend payments over the past 2 years.
- Total Returned Value: Investors who held CANC shares during this period received a total of $0.90 per share in dividend income.
- Latest Payout: The most recent dividend of $0.02/share was paid 219 days ago, on December 11, 2025.
- Yield & Schedule: CANC currently pays dividends yearly with an annual yield of 0.05%.
- Dividend Growth: Since 2023, the dividend payout has decreased by 86.9%, from $0.15 to $0.02.
Company News
We discuss attractive investment opportunities within the healthcare industry.
In September, Biden unveiled a $240 million investment to combat cancer, augmenting the administration’s “Cancer Moonshot”, an initiative with an array of new health resources. The funding, allocated through the recently established Advanced Research Projects Agency for Health (ARPA-H) will support researchers engaged in projects spanning...
Tema ETFs is redefining thematic investing by prioritizing long-term structural trends and precision in security selection, diverging from the industry norm of chasing short-lived market fads. This innovative approach was the focal point of a virtual session hosted by Benzinga’s “ETFs Unlocked,” moderated by Benzinga’s Aaron Bry. Yuri Kh...
The rapid emergence of the ETF industry, marked by its AuM growth from $1 trillion to $10 trillion this past decade, was driven by passive indexed funds which thrived in a low-rates, low-volatility environment. These funds offered low cost, low differentiation solutions to retail investors. As institutional investors overtake retail investors...
Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics ETF (NASDAQ:HRST) launches on the NASDAQ exchange...
